For the first time, investigators have revealed clinical trial performance for a triplet containing Bristol Myers’ PD-1/LAG-3 combo Opdualag and the CTLA4 inhibitor Yervoy in advanced melanoma. The three-drug regimen shrank tumors in 27 of 46 first-line melanoma patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,